Related content

Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a firstline treatment for Japanese patients with metastatic colorectal cancer

By                    

Molecular and Clinical Oncology, Vol. 2, Iss. 1, 2014-01 ,pp. : 134-138

Spandidos Publications

Access to resources Recommend Favorite

XELIRI regimen plus continuous treatment with bevacizumab is well-tolerated and effective in metastatic colorectal cancer patients in a secondline setting involving the sequential administration of XELOX and XELIRI

By                        

Molecular and Clinical Oncology, Vol. 2, Iss. 5, 2014-01 ,pp. : 827-832

Spandidos Publications

Access to resources Recommend Favorite

Modified FLOX as first-line chemotherapy for metastatic colorectal cancer patients in the public health system in Brazil: Effectiveness and cost-utility analysis

By Nebuloni  

Molecular and Clinical Oncology, Vol. 1, Iss. 1, 2013-01 ,pp. : 175-179

Spandidos Publications

Access to resources Recommend Favorite

KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin or irinotecanbased treatment

By                  

Molecular and Clinical Oncology, Vol. 2, Iss. 3, 2014-01 ,pp. : 356-362

Spandidos Publications

Access to resources Recommend Favorite

Gene expression markers in circulating tumor cells may predict bone metastasis and response to hormonal treatment in breast cancer

By                    

Molecular and Clinical Oncology, Vol. 1, Iss. 6, 2013-01 ,pp. : 1031-1038

Spandidos Publications

Access to resources Recommend Favorite